Huida Gene: HuidaGene's gene-editing therapy named rare pediatric drug by FDA

HuidaGene Therapeutics' investigational gene-editing therapy, called HG302, for Duchenne muscular dystrophy (DMD) has been granted a rare pediatric drug designation by the U.S. Food and Drug Administration (FDA). This status is intended to incentivize companies to develop treatments for rare and serious or life-threatening diseases affecting people under age 18. If a product with the [...] The post HuidaGene's gene-editing therapy named rare pediatric drug by FDA appeared first on Muscular Dystrophy News.